Drug Trial Radar · NCT05409027
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jul 23, 2021
Primary completion
Mar 10, 2022
Study completion Feb 7, 2024
Sponsor
- Lead sponsor
- Sparrow PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
Conditions
- Type 2 Diabetes Mellitus in Obese
- Obesity
- Type2Diabetes
Interventions
SPI-62Drug
SPI-62 is supplied as 1 mg tablets for oral dosing.
Cortisone-d8Drug
Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (Cmax)Time frame: Days 1 through 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ProSciento
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.